Clinical Trial Update: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

View source ↗

Summary

A recruiting clinical trial evaluating immunological senescence phenotype as a potential resistance profile to pembrolizumab in relapsed/refractory Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: Hodgkin Lymphoma | Status: RECRUITING